These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27835909)

  • 1. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.
    Wu R; Cheng YJ; Zhu LL; Yu L; Zhao XK; Jia M; Wen CH; Long XZ; Tang T; He AJ; Zeng YY; Ma ZF; Zheng Z; Ni MZ; Cai GJ
    Oncotarget; 2016 Dec; 7(49):81870-81879. PubMed ID: 27835909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans.
    Yang F; Yang Y; Zhu Q; Chen SA; Fu X; Yan S; Meng C; Ma L; Sun X; Xu J; Luo X; Xing Q
    J Investig Dermatol Symp Proc; 2015 Jul; 17(1):29-31. PubMed ID: 26067314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug eruptions induced by allopurinol associated with HLA-B*5801.
    Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H
    Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pharmacogenomic polymorphisms on allopurinol-induced cutaneous adverse drug reactions in Thai patients.
    Sornsamdang G; Satapornpong P; Jinda P; Jantararoungtong T; Koomdee N; Tempark T; Klaewsongkram J; Rerkpattanapipat T; Rerknimitr P; Tuchinda P; Chularojanamontri L; Tovanabutra N; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Srisuttiyakorn C; Srinoulprasert Y; John S; Biswas M; Sukasem C
    BMC Med Genomics; 2024 Apr; 17(1):101. PubMed ID: 38654296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed drug eruption in a patient of HLA-B*58:01 negative after allopurinol administration: A case report.
    Zhang R; Geng H; Du J; Liu M
    J Clin Pharm Ther; 2022 Jun; 47(6):841-843. PubMed ID: 35118681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.
    Chiu ML; Hu M; Ng MH; Yeung CK; Chan JC; Chang MM; Cheng SH; Li L; Tomlinson B
    Br J Dermatol; 2012 Jul; 167(1):44-9. PubMed ID: 22348415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.
    Sato T; Cheng CL; Park HW; Kao Yang YH; Yang MS; Fujita M; Kumagai Y; Tohkin M; Saito Y; Sai K
    Clin Transl Sci; 2021 May; 14(3):1002-1014. PubMed ID: 33382928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.
    Jarjour S; Barrette M; Normand V; Rouleau JL; Dubé MP; de Denus S
    Pharmacogenomics; 2015; 16(7):755-67. PubMed ID: 25965122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis.
    Sukasem C; Sririttha S; Chaichan C; Nakkrut T; Satapornpong P; Jaruthamsophon K; Jantararoungtong T; Koomdee N; Medhasi S; Oo-Puthinan S; Rerkpattanapipat T; Klaewsongkram J; Rerknimitr P; Tuchinda P; Chularojanamontri L; Tovanabutra N; Suvannang N; Rungrotmongkol T; Saokaew S; Aekplakorn W; Puangpetch A
    Pharmacogenomics J; 2021 Dec; 21(6):682-690. PubMed ID: 34175889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
    Yu KH; Yu CY; Fang YF
    Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.
    Cao ZH; Wei ZY; Zhu QY; Zhang JY; Yang L; Qin SY; Shao LY; Zhang YT; Xuan JK; Li QL; Xu JH; Xu F; Ma L; Huang HY; Xing QH; Luo XQ
    Pharmacogenomics; 2012 Jul; 13(10):1193-201. PubMed ID: 22909208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
    Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
    BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of cutaneous adverse drug reactions.
    Aihara M
    J Dermatol; 2011 Mar; 38(3):246-54. PubMed ID: 21342226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
    Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
    Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
    J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
    van Nguyen D; Chu HC; Vidal C; Fulton RB; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Chu HH; Thanh Thuc HT; Minh Le HT; van Nunen S; Anderson J; Fernando SL
    Pharmacogenomics; 2021 Jan; 22(1):1-12. PubMed ID: 33356553
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles.
    He N; Min FL; Shi YW; Guo J; Liu XR; Li BM; Zhou JH; Ou YM; Liao JX; Liao WP
    Seizure; 2012 Oct; 21(8):614-8. PubMed ID: 22818943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.
    Yang Y; Chen S; Yang F; Zhang L; Alterovitz G; Zhu H; Xuan J; Yang X; Luo H; Mu J; He L; Luo X; Xing Q
    Pharmacogenomics J; 2017 Dec; 17(6):501-505. PubMed ID: 27527109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.